Hangzhou Tigermed Consulting - Asset Resilience Ratio
Hangzhou Tigermed Consulting (300347) has an Asset Resilience Ratio of 0.11% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Hangzhou Tigermed Consulting strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Hangzhou Tigermed Consulting's Asset Resilience Ratio has changed over time. See 300347 equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Hangzhou Tigermed Consulting's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Hangzhou Tigermed Consulting (300347) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥32.71 Million | 0.11% |
| Total Liquid Assets | CN¥32.71 Million | 0.11% |
Asset Resilience Insights
- Limited Liquidity: Hangzhou Tigermed Consulting maintains only 0.11% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hangzhou Tigermed Consulting Industry Peers by Asset Resilience Ratio
Compare Hangzhou Tigermed Consulting's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.12% |
|
Spectral Med Inc
TO:EDT |
Diagnostics & Research | 11.67% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Hangzhou Tigermed Consulting (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Hangzhou Tigermed Consulting.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.21% | CN¥59.46 Million ≈ $8.70 Million |
CN¥28.36 Billion ≈ $4.15 Billion |
-0.05pp |
| 2024-12-31 | 0.26% | CN¥74.85 Million ≈ $10.95 Million |
CN¥28.67 Billion ≈ $4.20 Billion |
+0.12pp |
| 2023-12-31 | 0.14% | CN¥42.14 Million ≈ $6.17 Million |
CN¥29.68 Billion ≈ $4.34 Billion |
+0.05pp |
| 2022-12-31 | 0.09% | CN¥24.95 Million ≈ $3.65 Million |
CN¥27.45 Billion ≈ $4.02 Billion |
-0.03pp |
| 2021-12-31 | 0.12% | CN¥29.18 Million ≈ $4.27 Million |
CN¥23.74 Billion ≈ $3.47 Billion |
-0.01pp |
| 2020-12-31 | 0.13% | CN¥26.00 Million ≈ $3.80 Million |
CN¥19.51 Billion ≈ $2.85 Billion |
-0.78pp |
| 2019-12-31 | 0.91% | CN¥68.83 Million ≈ $10.07 Million |
CN¥7.57 Billion ≈ $1.11 Billion |
+0.90pp |
| 2018-12-31 | 0.01% | CN¥587.40K ≈ $85.96K |
CN¥4.68 Billion ≈ $684.54 Million |
-2.11pp |
| 2017-12-31 | 2.12% | CN¥76.04 Million ≈ $11.13 Million |
CN¥3.58 Billion ≈ $524.33 Million |
-5.19pp |
| 2016-12-31 | 7.31% | CN¥174.55 Million ≈ $25.54 Million |
CN¥2.39 Billion ≈ $349.49 Million |
+6.35pp |
| 2015-12-31 | 0.96% | CN¥15.40 Million ≈ $2.25 Million |
CN¥1.61 Billion ≈ $235.60 Million |
-0.64pp |
| 2014-12-31 | 1.59% | CN¥21.65 Million ≈ $3.17 Million |
CN¥1.36 Billion ≈ $198.66 Million |
-8.06pp |
| 2013-12-31 | 9.65% | CN¥78.00 Million ≈ $11.41 Million |
CN¥808.01 Million ≈ $118.24 Million |
-- |
About Hangzhou Tigermed Consulting
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing … Read more